- Home
- Search Results
Search Results
Filter :
FILTER BY keyword:
FILTER BY author:
- Abdulqadir J. Nashwan [1]
- Adel Issam Al Bozom [1]
- Ahmed Hatim [1]
- Ahmed Hatim. Mohamed [1]
- Amer Ali Farooqi [1]
- Anas Mohamed Babiker [1]
- Awni Alshurafa [1]
- Fateen Ata [1]
- Fathima Z. Zahir [1]
- Habib Ur Rehman [1]
- Mhd Baraa Habib [1]
- Mohamed A. Yassin [1]
- Mohammed Alkhatib [1]
- Mousa Ahmad Al Hiyari [1]
- Muhammad Abu Bakar [1]
- Phool Iqbal [1]
- Sunil Hassan Koya [1]
- Zohaib Yousaf [1]
- [+] More [-] Less
FILTER BY language:
FILTER BY content type:
FILTER BY publication:
FILTER BY affiliation:
- Department of Hematology, Hamad Medical Corporation, Qatar [1]
- Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: [email protected];[email protected] [1]
- Department of Internal Medicine, Hamad Medical Corporation, Qatar Email: [email protected] [1]
- Department of Internal Medicine, New York Medical College/Metropolitan Hospital Center, New York, USA [1]
- Department of Medical ICU, Hamad Medical Corporation, Qatar [1]
- Department of Medical Oncology/Hematology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar [1]
- Department of Nursing for Education & Practice Development, Hamad Medical Corporation, Doha, Qatar [1]
- [+] More [-] Less
FILTER BY article type:
FILTER BY access type:
Dilemma of Thrombolysis in a patient with high-risk Pulmonary Embolism with severe Thrombocytopenia: A case report
Background: Managing a high-risk pulmonary embolism (PE) in a critically ill patient with severe thrombocytopenia can present a challenging dilemma. There is a high risk of fatal bleeding due to anticoagulation in high-risk PE with thrombocytopenia; therefore risks and benefits are balanced while dealing with such a critical scenario.
Case Report: We present a case of a female patient with thrombocytopenia who was admitted for management of lymphoma. Her hospital course was complicated by high-risk PE leading to acute respiratory failure and hypotension necessitating urgent transfer to the medical intensive care unit. She was intubated and placed on mechanical ventilation. Multiple cardiac arrests occurred due to compromised cardiac output from a severely dilated right ventricle on bedside transthoracic echocardiography. As a last resort to save her life in this critical state and severe thrombocytopenia she was given a half bolus dose of the recommended drug i.e. 50mg IV of Alteplase. Subsequently she stabilized and was extubated without any further complications.
Discussion: High-risk PE needs prompt management with anticoagulation to avoid fatal outcomes. However on the other hand anticoagulation carries a high risk of bleeding especially in patients with thrombocytopenia. These challenges prompt a modern perspective in situations where clear guidelines are absent.
Conclusion: We aim to discuss our contemporary clinical practice in managing such a complex case and highlight the need for further studies.
Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population
Background: Rituximab is used as second-line therapy in patients with immune thrombocytopenic purpura (ITP) who do not respond to first-line management. The response rate for Rituximab is variable in different populations ranging from 30% to 90%. The adverse effects of rituximab in patients with ITP range from infusion site reactions to the reactivation of hepatitis B virus and progressive multifocal leukoencephalopathy and interpopulation variation.
Methods: We conducted a single-center retrospective study in Qatar's National Center for Cancer Care & Research. The study included patients with chronic refractory ITP who received rituximab as second-line therapy. Descriptive and summary statistics were used to describe the sociodemographic parameters of the study cohort.
Results: Of the 41 patients with chronic ITP 26 were Arabs 12 were Asians and 3 were of other ethnicities. Rituximab was associated with an overall response rate of 80.4%. Arabic patients had the highest clinical response (84.6%) among the ethnicities with the lowest adverse effects (11.5%). Asians had a response rate of 66.6% and adverse effects were seen in 16.7% of the patients.
Conclusions: In chronic refractory ITP rituximab appears to have a better clinical response in the Arabic population with minimal toxicity than in other ethnicities.